Anne-Sophie Michallet
Overview
Explore the profile of Anne-Sophie Michallet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durot E, Kanagaratnam L, Zanwar S, Kaufman A, DSa S, Toussaint E, et al.
Am J Hematol
. 2024 Nov;
100(2):338-341.
PMID: 39588555
No abstract available.
2.
Stephan P, Bouherrou K, Guillermin Y, Michallet A, Grinberg-Bleyer Y
Cells
. 2024 Sep;
13(17.
PMID: 39273028
Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular efficacy of Ibrutinib, an irreversible inhibitor of Bruton tyrosine...
3.
Pignot P, Bahri H, Malartre S, Morisset S, Lebras L, Guillermin Y, et al.
Br J Haematol
. 2024 Aug;
205(4):1653-1656.
PMID: 39191676
No abstract available.
4.
Guieze R, Ysebaert L, Roos-Weil D, Fornecker L, Ferrant E, Molina L, et al.
Nat Commun
. 2024 Aug;
15(1):6822.
PMID: 39122717
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...
5.
Fouillet L, Daguenet E, Tavernier E, Ghesquieres H, Bachy E, Sesques P, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):270-274.
PMID: 37966973
No abstract available.
6.
Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, et al.
Cancer Med
. 2023 Aug;
12(16):16929-16944.
PMID: 37548369
Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis. Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of...
7.
Michallet A, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy M, et al.
Blood Adv
. 2023 Apr;
7(15):3936-3945.
PMID: 37026799
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07...
8.
Bourbon E, Chabane K, Mosnier I, Bouvard A, Thonier F, Ferrant E, et al.
J Mol Diagn
. 2023 Feb;
25(5):274-283.
PMID: 36773701
Current guidelines for patients with chronic lymphocytic leukemia (CLL) recommend mutation status determination of the clonotypic IGHV gene before treatment initiation to guide the choice of first-line therapy. Currently, commercially...
9.
Algrin C, Perol L, Chapiro E, Baseggio L, Maloum K, Settegrana C, et al.
Haematologica
. 2022 Dec;
108(6):1691-1696.
PMID: 36546425
No abstract available.
10.
Laloi L, Billotey N, Dumas P, Paul F, Villate A, Simand C, et al.
Cancer Med
. 2022 Dec;
12(6):7175-7181.
PMID: 36482507
Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at...